Your browser doesn't support javascript.
loading
The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure.
de Jong, Jan; Haddish-Berhane, Nahor; Hellemans, Peter; Jiao, James; Sukbuntherng, Juthamas; Ouellet, Daniele.
Afiliação
  • de Jong J; Janssen Research & Development, LLC, 3210 Merryfield Row, San Diego, CA, 92121, USA. jdejong1@its.jnj.com.
  • Haddish-Berhane N; Janssen Research & Development, LLC, Spring House, PA, USA.
  • Hellemans P; Janssen Research and Development, LLC, Beerse, NV, Belgium.
  • Jiao J; Janssen Research & Development, LLC, Raritan, NJ, USA.
  • Sukbuntherng J; Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
  • Ouellet D; Janssen Research & Development, LLC, Spring House, PA, USA.
Cancer Chemother Pharmacol ; 82(2): 299-308, 2018 08.
Article em En | MEDLINE | ID: mdl-29882017

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Omeprazol Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazóis / Pirimidinas / Omeprazol Tipo de estudo: Prognostic_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Chemother Pharmacol Ano de publicação: 2018 Tipo de documento: Article